Assessing prognosis in non-small-cell lung cancer: Avenues to a more complete picture?

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3209-3211

  Dubinett, Steven M ^a   Elashoff, David ^a   Meyerson, Matthew ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; DISEASE COURSE; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SURVIVAL RATE; DNA MICROARRAY; GENETICS; LUNG TUMOR; NOTE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 4344619218     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.931     Document Type: Editorial

References (22)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer 37:S4-66, 2001 (suppl 8)
2. Proctor RN: Tobacco and the global lung cancer epidemic. Nat Rev Cancer 1:82-86, 2001
3. Dy GK, Adjei AA: Novel targets for lung cancer therapy: Part I. J Clin Oncol 20:2881-2894, 2002
4. Liu ET, Karuturi KR: Microarrays and clinical investigations. N Engl J Med 350:1595-1597, 2004
5. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122:1037-1057, 2002
6. Meyerson M, Franklin WA, Kelley MJ: Molecular classification and molecular genetics of human lung cancers. Semin Oncol 31:4-19, 2004
7. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252, 2002
8. Rhee JS, Diaz R, Korets L, et al: TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 64:952-961, 2004
9. Aljada IS, Ramnath N, Donohue K, et al: Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer. J Clin Oncol 22:3218-3229, 2004
10. Thomas P, Khokha R, Shepherd FA, et al: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190:150-156, 2000
11. Ylisirnio S, Hoyhtya M, Makitaro R, et al: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633-1637, 2001
12. Bhattacharjee A, Richards WG, Staunton J, et al: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790-13795, 2001
13. Chen G, Gharib TG, Wang H, et al: Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100:13537-13542, 2003
14. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98:13784-13789, 2001
15. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
16. Yanagisawa K, Shyr Y, Xu BJ, et al: Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433-439, 2003
17. Endoh H, Tomida S. Yatabe Y, et al: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol 22:811-819, 2004
18. Wigle DA, Jurisica I, Radulovich N, et al: Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 62:3005-3008, 2002
19. Wigle DA, Tsao M, Jurisica I: Making sense of lung-cancer gene-expression profiles. Genome Biol 5:309, 2004
20. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
21. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
22. Dancey JE: Predictive factors for epidermal growth factor receptor inhibitors - The bull's-eye hits the arrow. Cancer Cell 5:411-415, 2004